The stock's fall snapped a four-day winning streak.

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Today, Benzinga 's options scanner spotted 33 uncommon options trades for Merck & Co. This isn't normal. The overall ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer: Cambridge, UK Thursday, May ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...